The review found no eligible studies for this question.
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with standard‐dose schedule (moderate certainty).
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with standard‐dose schedule (low certainty).
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with standard‐dose schedule (low certainty).
The review found no eligible studies for this question.
In primary dentition, high-frequency sugar consumption was associated with slightly higher, non-significant odds of caries (OR 1.13, 95% CI 0.23 to 5.44), with high heterogeneity (I2=83%; ungraded).
In permanent dentition, high-frequency sugar consumption was associated with non-significant 15% higher odds of caries (OR 1.15, 95% CI 0.88 to 1.52), with no heterogeneity (I2=0%; ungraded).
High-frequency sugar consumption was associated with 18% higher but non-significant odds of dental caries in Nigeria (OR 1.18, 95% CI 0.87 to 1.59; I2=36%; ungraded).
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in adverse effects: EPS: unspecified ‐ Versus low dose (greater than or… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in adverse effects: EPS: unspecified ‐ Versus standard‐lower dose… compared with ANY DOSE ‐ short term (moderate certainty).
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Prostate cancer: OR 1.04 (95% CI 0.98 to 1.09), not statistically significant. Umbrella review outcome-level evidence grade: Substantial effect unlikely.
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Type 2 diabetes: OR 0.63 (95% CI 0.56 to 0.69), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.